| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2893.2006.00768.X |
| P698 | PubMed publication ID | 17109680 |
| P50 | author | Laurent Castera | Q56995255 |
| P2093 | author name string | C Bonny | |
| V Leroy | |||
| D Dhumeaux | |||
| A Tran | |||
| L Alric | |||
| M Chevallier | |||
| C Henquell | |||
| A Abergel | |||
| K Barange | |||
| G Bommelaer | |||
| P-H Bernard | |||
| J P Bronowicki | |||
| H Lafeuille | |||
| C Darcha | |||
| S Ughetto | |||
| C Hezode | |||
| S Dubost | |||
| French multicenter study group | |||
| K Randl | |||
| N Martineau | |||
| P2860 | cites work | Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 |
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group | Q29614898 | ||
| Diagnosis, management, and treatment of hepatitis C | Q29620656 | ||
| Hematologic disorders associated with hepatitis C virus infection and their management | Q33349378 | ||
| Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients | Q34415766 | ||
| Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications | Q35596530 | ||
| Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial | Q42987199 | ||
| Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. | Q42993081 | ||
| Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis | Q43001248 | ||
| A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. | Q43033369 | ||
| Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. | Q43040369 | ||
| Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy | Q43049563 | ||
| Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment | Q44901526 | ||
| Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial | Q46790729 | ||
| Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. | Q47678268 | ||
| Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. | Q54018637 | ||
| P433 | issue | 12 | |
| P921 | main subject | ribavirin | Q421862 |
| multicenter clinical trial | Q6934595 | ||
| chronic hepatitis C | Q55779873 | ||
| P304 | page(s) | 811-820 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | Journal of Viral Hepatitis | Q15749962 |
| P1476 | title | Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b | |
| P478 | volume | 13 |
| Q38397145 | A meta-analysis platform methodology for determining the comparative effectiveness of antihepatitis C virus regimens |
| Q33394104 | A review of the treatment of chronic hepatitis C virus infection in cirrhosis |
| Q37534731 | Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection |
| Q42997291 | Antiviral treatment of chronic hepatitis C in clinical routine |
| Q27489596 | Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system |
| Q34365412 | Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan |
| Q37663921 | Direct-acting antiviral agents in patients with hepatitis C cirrhosis |
| Q43000439 | Editorial : Treatment of Patients With HCV-Related Cirrhosis With Peginterferon and Ribavirin: Swinging the Pendulum Toward Treatment |
| Q42281901 | Efficacy and safety of low-dose peginterferon alpha-2a plus ribavirin on chronic hepatitis C. |
| Q34243993 | Future treatment of patients with HCV cirrhosis |
| Q45353010 | Guidelines for the Management of Hepatitis C Virus Infection: First edition, May 2012, The Japan Society of Hepatology |
| Q28740552 | Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients |
| Q35226081 | Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study |
| Q42984419 | Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons |
| Q33816657 | Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response |
| Q37066393 | Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus |
| Q34334776 | Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. |
| Q45393757 | Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. |
| Q36290416 | Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs |
| Q42243719 | Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load |
| Q22305418 | Strategies to reduce hepatitis C virus recurrence after liver transplantation |
| Q34087387 | Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations |
| Q36142732 | Treatment of patients with HCV related cirrhosis: many rewards with very few risks. |
Search more.